[EN] STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)<br/>[FR] SOLUTIONS PARENTÉRALES AQUEUSES STABLES D'ANTI-INFLAMMATOIRES NON STÉROÏDIENS (AINS)
申请人:CADILA HEALTHCARE LTD
公开号:WO2021059234A1
公开(公告)日:2021-04-01
The invention relates to stable, aqueous, parenteral solutions comprising one or more nonsteroidal anti-inflammatory drugs (NSAIDs) and polyvinylpyrrolidone. The present invention also relates to processes for preparing such solutions.
Manufacture of High-Purity Meloxicam via Its Novel Potassium Salt Monohydrate
An improved procedure for the manufacture of 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (meloxicam) is described. The key intermediate of this protocol is the new potassium salt monohydrate of meloxicam, which makes possible the efficient removal of impurities, resulting in an environmentally friendly manufacturing process of the high-purity (>99
生产4-羟基-2-甲基-N-(5-甲基-1,3-噻唑-2-基)-2 H -1,2-苯并噻嗪-3-羧酰胺1,1-二氧化物的改进方法(美洛昔康)的描述。该方案的关键中间体是美洛昔康的新型钾盐一水合物,它使得有效去除杂质成为可能,从而实现了高纯度(> 99.90%)原料药的环保生产工艺。